Supplemental Figure 4a from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 4a. PTEN IHC assay validation and QD-FISH. A. Hematoxylin-and-eosin stained section of human prostate shows a focus of early prostatic adenocarcinoma.</p

Supplemental Figure 3c from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 3c. Comparison of western immunoblot results and PTEN IHC in EFM-19, CAMA-1, MDA-MB-415, MFM-223, HCC-1569, EFM192A, KPL-1, and BT549 human breast cancer cell lines.</p

Supplemental Figure 1 from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 1. Clinical trial schemata. Diagrammatic representation of the BCIRG 005 (A) and BCIRG 006 (B) adjuvant breast cancer clinical trials</p

Supplemental Figure 4b from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 4b. A serial section shows the same microscopic field after processing for PTEN localization by immunohistochemistry. Note the lack of immunostaining in the tumor cells.</p

Supplemental Figure 2 from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 2. Clinical outcome based on PTEN data availability. Kaplan Meier analysis was performed for patients with PTEN data available compared to patients without PTEN data available. Disease free survival (A, C) and overall survival (B, D) are shown for BCIRG 006 (HER2-amplified) (A, B) and BCIRG 005 (HER2-non-amplified) (C, D).</p

Supplemental Figure 3b from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 3b. Comparison of western immunoblot results and PTEN IHC in CAL-51, MDA-MB-451, HCC-1954, ZR-75-1, MCF7, CAL-120, and BT474 human breast cancer cell lines.</p

Supplemental Figure 4c from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 4c. QD-FISH for PTEN gene and chromosome 10 centromere demonstrate a loss of the PTEN gene in tumor cells.</p

Supplement Text AND ALL Supplement Figures from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplement Text AND ALL Supplement Figures</p

Supplemental Figure 3a from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Supplemental Figure 3a. PTEN IHC assay validation and scoring. PTEN IHC was performed on a panel of FFPE breast cancer cell pellets of known PTEN status confirmed by western immunoblot. (A.) Western immunoblot analyses for MDA-MB-468, CAL-148, MDA-MB-361, MT-3, and MDA-MB-436 human breast cancer cell lines are illustrated above with PTEN IHC illustrated below.</p

Data_Sheet_1_Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications.zip

BackgroundThere is an urgent need for harmonization between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology platforms and assays prior to defining appropriate correlates of protection and as well inform the development of new rapid diagnostic tests that can be used for serosurveillance as new variants of concern (VOC) emerge. We compared multiple SARS-CoV-2 serology reference materials to the WHO International Standard (WHO IS) to determine their utility as secondary standards, using an international network of laboratories with high-throughput quantitative serology assays. This enabled the comparison of quantitative results between multiple serology platforms.MethodsBetween April and December 2020, 13 well-characterized and validated SARS-CoV-2 serology reference materials were recruited from six different providers to qualify as secondary standards to the WHO IS. All the samples were tested in parallel with the National Institute for Biological Standards and Control (NIBSC) 20/136 and parallel-line assays were used to calculate the relevant potency and binding antibody units.ResultsAll the samples saw varying levels of concordance between diagnostic methods at specific antigen–antibody combinations. Seven of the 12 candidate materials had high concordance for the spike-immunoglobulin G (IgG) analyte [percent coefficient of variation (%CV) between 5 and 44%].ConclusionDespite some concordance between laboratories, qualification of secondary materials to the WHO IS using arbitrary international units or binding antibody units per milliliter (BAU/ml) does not provide any benefit to the reference materials overall, due to the lack of consistent agreeable international unit (IU) or BAU/ml conversions between laboratories. Secondary standards should be qualified to well-characterized reference materials, such as the WHO IS, using serology assays that are similar to the ones used for the original characterization of the WHO IS.</p